The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives

Login or register to view PDF.
Creative Commons Licence
Abstract

Diabetes is a complex metabolic disorder affecting the glucose status of the human body. Chronic hyperglycaemia related to diabetes is associated with end organ failure. The clinical relationship between diabetes and atherosclerotic cardiovascular disease is well established. This makes therapeutic approaches that simultaneously target diabetes and atherosclerotic disease an attractive area for research. The majority of people with diabetes fall into two broad pathogenetic categories, type 1 or type 2 diabetes. The role of obesity, adipose tissue, gut microbiota and pancreatic beta cell function in diabetes are under intensive scrutiny with several clinical trials to have been completed while more are in development. The emerging role of inflammation in both type 1 and type 2 diabetes (T1D and T1D) pathophysiology and associated metabolic disorders, has generated increasing interest in targeting inflammation to improve prevention and control of the disease. After an extensive review of the possible mechanisms that drive the metabolic pattern in T1D and T2D and the inflammatory pathways that are involved, it becomes ever clearer that future research should focus on a model of combined suppression for various inflammatory response pathways.

Disclosure
The authors have no conflicts of interest to declare.
Correspondence
Sotirios Tsalamandris, Vasilissis Sofias 114, PO 11528, Hippokration Hospital, Athens, Greece. E: stsalamandris@hotmail.com
Received date
21 December 2018
Accepted date
18 February 2019
Citation
European Cardiology Review 2019;14(1):50–9
DOI
https://doi.org/10.15420/ecr.2018.33.1
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Diabetes is a multifaceted metabolic disorder affecting the glucose status of the human body. Impaired glucose tolerance and hyperglycaemia are the main clinical and diagnostic features and the result of an absolute or relative insulin deficiency or resistance to its action. Chronic hyperglycaemia associated with diabetes can result in end organ dysfunction and failure which can involve the retina, kidneys, nerves, heart and blood vessels.1 The clinical relationship between diabetes and atherosclerotic cardiovascular disease are well established, with the risk for cardiovascular disease (CVD) being significantly elevated in patients with diabetes.2,3

Moreover, CVD typically occurs one to two decades earlier in people with diabetes, with more aggressive, severe and diffuse distribution.4,5 The first WHO global report on diabetes published in 2016 demonstrates that the number of adults living with diabetes has almost quadrupled since 1980 to 422 million adults and this is expected to rise to 552 million by 2030.6,7 Thus, the need for effective novel therapeutic approaches for the treatment and/or prevention of diabetes and atherosclerotic disease is crucial.

Traditionally, the majority of cases of diabetes fall into two broad pathogenetic categories, type 1 (T1D) and type 2 (T2D). However, in some people this rigid classification is not applicable because other genetic, immunological or neuroendocrinological pathways are involved in its pathogenesis. T1D is related to an absolute lack of insulin due to a vaguely understood mechanism, where an immune-mediated destruction of pancreatic beta cells is the hallmark of the disorder, with hyperglycaemia only emerging when more than 90% of the beta cells are lost.8 T2D is the most common form of diabetes, accounting for 90–95% of cases. Its development is secondary to a relative insulin deficiency but the primary defect is insulin resistance.9

Various proposals and hypotheses have been developed to describe the mechanisms which are usually involved in the propagation of diabetes, mainly focusing on T2D. The increase in prevalence of the condition has been related to well-recognised risk factors, such as the adoption of a western lifestyle, sedentary lives, lack of physical activity and an energy-dense diet.10,11 Genetic predisposition, ethnicity and ageing are not modifiable risk factors for T2D, while others, such as being overweight or obese, an unhealthy diet, insufficient physical activity and smoking are modifiable through behavioural and environmental changes. However, increasing evidence has shown that inflammatory pathways are the principal, common pathogenetic mediators in the natural course of diabetes under the stimulus of the risk factors described above.12

In this article, we will highlight the emerging role of inflammation in the pathophysiology of diabetes and we will analyse the implicated inflammatory pathways and biomarkers of inflammation in diabetes and metabolic diseases. The focus of this article is to provide an overview of the current state of knowledge on anti-inflammatory therapies for diabetes, along with perspectives on future therapies for the disease.

Historical Perspectives

Observational studies provided the first evidence for the possible association between inflammation and diabetes. Over a century ago, the administration of high doses of sodium salicylate led to decreased glycosuria in people with a suspected or definite diagnosis of diabetes.13,14 Later studies on the role of inflammation in diabetes, revealed that this hypoglycaemic action was related to the inhibition of the serine kinase IkappaB kinase-beta (IKKbeta), which correlates with the post-receptor action of insulin.15

A landmark study to correlate inflammation with diabetes was conducted in animal models by Hotamisiligil et al., in 1993 and it revealed that the role of tumour necrosis factor-alpha (TNF-alpha) in obesity and particularly in insulin resistance and diabetes.16 Epidemiologic associations of inflammation with obesity and T2D were made when circulating concentrations of markers and mediators of inflammation and acute-phase reactants including fibrinogen, C-reactive protein, interleukin (IL)-6, plasminogen activator inhibitor-1, sialic acid and white cells, have been shown to be elevated in these conditions.17–21 Over the next decades, numerous studies on human and animal models provided further supporting evidence for the role of inflammation in the initiation and progression of diabetes.12,22 Accumulative evidence suggests that chronic activation of pro-inflammatory pathways in target cells of insulin action may contribute to obesity, insulin resistance and related metabolic disorders including T2D.22 The identification of potential pathways connecting inflammation to diabetes has produced growing interest in targeting inflammation to help prevent and control diabetes and related conditions, as well as improving risk stratification for diabetes by using inflammatory biomarkers as potential indexes.23,24

Inflammation in Type 1 Diabetes

T1D is an autoimmune disorder characterised by a selective, specific destruction of insulin-producing pancreatic beta cells, without apparent pathological alterations of other Langerhans cells.25 However, T1D shows significant heterogeneity in regard to the age of onset, severity of autoimmune response and efficacy of therapy, while it has also been demonstrated that both humoral and cellular immunity is involved in the pathogenesis of T1D.26–28 The first theories about predisposition support that environmental trigger factors in early life, such as infections, nutrition and chemicals that are able to activate self-targeting immune cascades, remain applicable even though the initial event is still unclear.29,30

Inflammatory Infiltrates in Type 1 Diabetes

Progress in understanding the pathophysiology of T1D has been made in parallel with the advances in the field of immunology. The predominant theory is that the beta cell pancreatic islets in patients with T1D are inflamed, called insulitis, through the course of T1D. Anderson et al., demonstrated that failure in both central and peripheral immune tolerance mechanisms contribute to the emergence of autoreactive T cells in the periphery of non-obese mice with diabetes.31 Regulatory T cells (Tregs) have been shown to also be defective in this autoimmune disease setting, along with evidence from animal models demonstrating the participation of both CD4+ and CD8+ T cells (effector T-cells/Teff) in the development of T1D as they target several beta cell autoantigens and related peptide epitopes.32–35 Moreover, by using adoptive T-cell transfer models of T1D, it has been demonstrated that T-cell subtypes are capable of inducing destructive peri-islet inflammatory infiltrate and overt diabetes.36,37 This was further depicted in human studies using pancreas samples obtained post mortem from subjects diagnosed with recent-onset T1D.27,38

Inflammatory Mediators In Type 1 Diabetes

Open in new tab
Open ppt

Interestingly, the immune B cell (CD20+) profile also changes during disease progression, as initial studies found they align closely with the migration of CD8+ T cells, following two different patterns, either that of high or low infiltration in islets as reported by Wilcox et al.27,38 Macrophages are also critical mediators of islet inflammation due to their ability to secrete cytokines, such as Interleukin 1 beta (IL-1beta) and tumour necrosis factor alpha (TNF-alpha) and produce reactive oxygen species (ROS).27,39 Additional studies have shown that the surrounding pancreatic exocrine tissue is abundant in both lymphocytes and neutrophils in T1D and it is suspected that these cells might also contribute to the evolution of disease.40,41 In some studies, dendritic cells, natural killer (NK) cells and NKT cells have also been found in the islet infiltrate and may have a partial role in the whole process, however, it seems that overall the interaction among different cell types regulates diabetes progression.42,43

Mediators of Inflammation in Type 1 Diabetes

The three cytokines that seem to be implicated in the inflammation of pancreatic beta cells in T1D, are the synergic action of interferon gamma (IFN-gamma) and the innate inflammatory cytokines TNF-alpha and IL-1beta.44 The combined action of these inflammatory molecules results in the upregulation of inducible nitric oxide synthase (iNOS), with subsequent production of nitric oxide (NO).45 However, even though ROS plays a role in beta cell destruction, more recent studies have demonstrated that NO is not implicated in the damage of pancreatic beta cell.46 Furthermore, studies demonstrating that the biology of the beta cell could directly influence the response to an inflammatory environment, through specific gene-guided modulation of beta cell apoptosis induced by IFN-gamma modulated by the PTPN2 gene (Figure 1).47

Representative Clinical Trials Of Anti-Inflammatory

Open in new tab
Open ppt

The mechanisms mentioned above strongly suggest that multiple pathways may exist which can contribute to pancreatic beta cell death. During this process, the control and regulation of local inflammatory cytokines production are likely to be critical factors in determining the outcome of the autoimmune progression. The disruptive effects of inflammatory and autoimmune-mediated pancreatic islet attack may lead to a vicious cycle where initial cytokine stress may urge the metabolic stress and an additional loss in beta cell function.48

Anti-Inflammatory Trials on Type 1 Diabetes

Given the obvious genetic influences in the initiation and progression of T1D, the immune cell type and the pattern that occurs in any given patient offers an important perspective on the design of clinical trials intended to slow or terminate the progression of the disease. Two initial clinical trials with rituximab, a monoclonal anti-CD20 antibody, were only partially successful.49,50 Furthermore, strategies are being developed targeting the antigen-specific T-cell response, such as the application of plasmid DNA (pDNA) vaccination with promising results.51 Moreover, two humanised anti-CD3 monoclonal antibody (mAbs), teplizumab and otelixizumab, have been evaluated in people with new and recently diagnosed T1D and showed a reduced rate of loss of beta cell function in the majority of participants.52

Cytokines are another promising target for therapy for T1D, given their involvement in the process of beta cell pathology. IL-1beta and TNF-alpha appear to be attractive initial targets for designing clinical trials based on this concept. A pilot study examined the effects of an anti-TNF-alpha therapy, etanercept, on paediatric patients newly diagnosed with T1D and demonstrated an increased endogenous insulin production and better metabolic control.53 Administration of alpha-1 antitrypsin (AAT), an anti-inflammatory serum protein, to a small group of people with T1D resulted in a reduced IL-1beta response in monocytes and dendritic cells and improved beta cell function.54 Furthermore, given the broad anti-inflammatory properties of vitamin D, it has also been identified as a potential therapeutic target.55 However, small studies of vitamin D supplementation in recent onset T1D have only resulted in modest beta cell protection.56,57

On a larger scale, interleukin-1 receptor antagonist (IL-1RN) and human monoclonal IL-1beta antibody were employed in two randomised, placebo-controlled trials in people with recent onset T1D.58 Canakinumab and anakinra were found to be safe but they were not effective as single immunomodulatory drugs in recent-onset T1D and they did not result in preserved beta cell function, as measured by stimulated C-peptide area under the curve (Table 1).

In conclusion, the immunotherapeutic trials that have been completed in human T1D have always focused on patients after clinical onset of diabetes, well after the establishment of targeted adaptive immune responses towards beta cell islets. Targeting these factors is likely to preserve remaining beta cell function, but curative treatments can only be realistically achieved by attempting at the same time to replace part of the beta cell mass that has been lost during the autoimmune process.

Metabolic Disorders and Inflammation in Type 2 Diabetes

Inflammation in Type 2 Diabetes

Several pathophysiological studies have strengthened our understanding of insulin resistance and secretion in the course of disease onset and progression.59,60 Subjects at risk of T2D display an initial state of insulin resistance compensated by hypersecretion of insulin in the beta cells. However, in the clinical course of the disease this pancreatic functional reserve is eventually unable to cope with the required insulin secretion and by the time diabetes is diagnosed, beta cells are no longer able to secrete enough insulin.61 Although the relative contribution of beta cell dysfunction and insulin resistance can vary in people with T2D, it is generally accepted that abnormal insulin sensitivity precedes the clinical diagnosis of diabetes by up to 15 years.62 Therefore, along with mechanistic studies investigating mechanisms forming the basis of insulin resistance, more recent research has also focused on the pathways leading to beta cell failure.63

The Role of Adipose Tissue and Obesity

There has been intensive research conducted into the pathophysiology of diabetes and its association with obesity and the biological role of adipose tissue. As addressed before, insulin resistance is a key component in the course of T2D. Liver and muscles have long been recognised as major contributors of systemic insulin resistance.64 Fat accumulation in the liver (steatosis) precedes overt T2D, is commonly associated with obesity and is considered a major determinant of the reduced hepatic insulin sensitivity resulting in fasting hyperglycaemia.65–67 Furthermore, it is now well accepted that the accumulation of energy due to excessive calorie intake and the lack of physical activity leads initially to fat accumulation in the subcutaneous tissue and later to other tissue compartments such as the liver, pancreas, muscles, perivascular and pericardium.67 This fat accumulation increases tissues’ insulin resistance, while pancreatic fat accumulation further determines beta cell dysfunction.64,68

Obesity and its associated conditions including metabolic syndrome, hypertension and dyslipidaemia, is positively associated with concentrations of inflammatory biomarkers, which are predictive of insulin resistance and the incidence of T2D and CVD.69–71 Obesity and metabolic syndrome specifically comprise a cluster of diseases associated with too much food and insufficient physical activity, conditions where sub-acute chronic inflammation is a common and potentially unifying mechanistic cause, accompanied by activation of at least two major inflammatory pathways, stress-activated Jun N-terminal kinases (JNK) and the transcription factor NF-kappaB.12,16,72–77 This inflammatory state via production of pro-inflammatory cytokines, is further amplified by adipokines, though a number of studies have demonstrated that adipokines stimulate additional inflammatory responses in obesity and promote obesity-induced metabolic and cardiovascular diseases.78

Animal studies have demonstrated that brown adipose tissue (BAT) has an important role in regulating energy and glucose homeostasis and is associated with peripheral insulin resistance and glucose levels.79–81 However, white adipose tissue (WAT) and mainly visceral WAT (around the trunk, upper body or abdomen) appears to be the major source of inflammatory markers in T2D, but also a target of the inflammatory process in people with diabetes. It produces cytokines and several other bioactive substances involved in the inflammatory pathways, such as TNF-alpha, IL-1, IL-6, IL-10, leptin, adiponectin, monocyte chemoattractant protein, angiotensinogen, resistin, chemokines, serum amyloid protein, and many others collectively referred to as adipokines.82–85 Further infiltration of adipose tissue by macrophages and immune cells (B cells and T cells) trigger local and systemic chronic low-grade inflammation, by producing more cytokines and chemokines that serve as a pathologic link between obesity, insulin resistance and diabetes.86

The Role of Gut Microbiota in Type 2 Diabetes

The role of the gut in the pathophysiology of diabetes can be approached from two different viewpoints. Studies have suggested that several mechanisms may be involved in weight loss and diabetes control after bariatric surgery, beyond malabsorption or anatomical restriction.87 Indeed, complex changes in multiple gut hormones have been shown after bariatric procedures and have been proposed as adjunctive mechanisms for short- and long-term positive metabolic effects, serving as possible novel therapeutic approaches to obesity and insulin resistance.88,89

In the past few years, a two-way relationship between the gut microbiome in the host’s energy balance and immune function has been demonstrated.90 The gut microbiome seems to differ between obese and lean subjects, flora composition influences metabolism and inversely, diet and metabolic status influence the composition of the gut flora, while a faecal microbiome transplantation from lean donors to insulin-resistant subjects results in beneficial metabolic effects.91–94 It has been postulated that products from the gut microbiome may interact with the immune system inducing a tissue metabolic modification, which feeds the molecular origin of the low-grade inflammation that characterises the onset of obesity and diabetes.95

An altered gut microbiota can directly affect immune cells in the gut and indirectly affect immune cells via microbial products including LPS, metabolites and short chain fatty acid (SCFAs), all of which can affect adipogenesis and/or insulin resistance.96–101 Lipopolysaccharide (LPS) is believed to cause low-grade inflammation mediated by the induction of inflammatory cytokines by immune cells and adipocytes, while SCFAs can modulate gene expression of human monocytes and reduce pro-inflammatory cytokine and chemokine production.102 SCFAs can also promote regulatory T-cell generation through several pathways, thereby suppressing the function of inflammatory T cells. These are able to block IFN-gamma inducible protein 10 (IP-10) release in human colonic sub-epithelial myofibroblasts, acting not only on immune cells systemically but also on intestinal tissue cells locally.103,104

The Role of Pancreatic Beta Cell Failure in Type 2 Diabetes

Independent of the aetiopathogenetic mechanism among the different types of diabetes, the common pathway seems to be the inflammation in the pancreatic Langerhans beta cell islets (insulitis), in the concept of an auto-inflammatory process, which results in reduction in both beta cell number and function.105 It has been suggested that in people with a genetic predisposition, the ‘stressed’ beta cell may stimulate local inflammation and modify the balance between beta cell mass and function in the islets of Langerhans.106,107 Several experimental models as well as observational studies in humans have demonstrated that macrophages play a key role in the islet inflammation seen in T2D.108–111 Inflammasome/IL-1beta signalling is the most common, well-studied and high-impact pathway activated in islets of multiple T2D models that cause beta cell dysfunction.112,113 It is likely that other immune cell types are involved in islet inflammation in T2D, while islet autoimmunity has also been suggested to contributes to beta cell functional decline during the course of T2D.114,115

Among factors that stimulate islet macrophages to secrete IL-1beta in vivo in human islets are amyloid polypeptide, free fatty acids (FFAs) and endocannabinoids.110,111,116 However, it has been assumed that hyperglycaemia is produced initially in the inflammation in pancreatic beta cells by inducing apoptotic mechanisms.117 ALPHA particular pathway was proposed by Maedler et al. who showed that hyperglycaemia may induce the production of IL-1beta by stimulating pro-apoptotic receptor FFAs on beta cells.118

The Vicious Cycle Of Inflammation In Various Target Organs In Type 2 Diabetes

Open in new tab
Open ppt

FFAs can also produce and secrete IL-1beta and IL-1-dependent pro-inflammatory cytokines in pancreatic islets and thus to reduce the inflammation. In addition, after its initial secretion, IL-1beta regulates its production in pancreatic beta cells by auto stimulation, while this process also increases nitric oxide production leading to reduction in ATP concentration in the mitochondria, which can cause further beta cell dysfunction and reduced insulin secretion.119–122 Oxidative stress may also potentiate the generation of ROS along with other pro-inflammatory cytokines and chemokines in the beta cells that disrupts the blood flow into them and destroys their function.108,123,124

Experimental studies have confirmed that IL-6 induces apoptosis in pancreatic islets together with other inflammatory cytokines and acts as a predictor and pathogenic marker for the progression of T2D.69,124,125 TNF-alpha is also considered to play an essential role, by creating a linkage among insulin resistance, obesity and islet inflammation.125 Its overproduction in adipose tissue seems to feed the inflammation and beta cell death in pancreatic islets and produces additional insulin resistance in peripheral tissues.126,127

Evidence of Inflammation in Other Organs in People with Type 2 Diabetes

Immune system activation is highly related to T2D incidence and progression and adaptive and innate immunity are involved in adipose tissue inflammation. The phenotype switching of macrophages from predominantly anti-inflammatory M2-type to increased proportions of pro-inflammatory M1-type macrophages plays a crucial role in the initiation and amplification of islet inflammation.128 However, the evidence shows that the recruitment of B cells and T cells precedes adipose tissue infiltration by macrophages.86

Moreover, several other organs have been reported to participate in the metabolic homeostasis and inflammatory state in T2D, such as the liver, the neural system and possibly skeletal muscle.129–133 However, more research is needed to support this evidence (Figure 2).

Current Knowledge on Diabetes Treatments

Drugs with Pleiotropic Effects

The current therapeutic approaches to T2D have anti-inflammatory properties in addition to their major modes of action. Non-pharmacological therapies, such as lifestyle interventions, but also pharmacological and bariatric surgical approaches for weight loss, appears to reduce inflammation assessed as circulating CRP and IL-6 concentrations, and improves cardiovascular and all-cause mortality.134–138

Statins also have anti-inflammatory properties beyond their ability to lower levels of low-density lipoproteins (LDL) cholesterol. The Justification for the Use of Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) demonstrated that rosuvastatin reduced high-sensitivity CRP along with LDL cholesterol, however the effects of statins on glycaemic control are conflicting, implying that targeting inflammation with statins does not improve glycaemia and therefore does not provide an integrated anti-inflammatory approach for diabetes and CVD.139–141

Anti-diabetic agents, including insulin, have intrinsic anti-inflammatory effects associated with their primary mechanisms of action and are also associated with reductions in inflammatory markers. Insulin itself decreases NF-kappaB activity in peripheral blood mononuclear cells which reduces inflammation.142 The anti-inflammatory actions of thiazolidinediones through binding and activation to the peroxisome proliferator-activated receptor gamma (PPARgamma), seems to be related to trans-repression of NF-kappaB and reduced expression of NF-kappaB targets.143

In addition to its metabolic effects, metformin has anti-inflammatory actions that appear to be independent of glycaemia and are most prominent in immune cells and vascular tissues.144–150 Dipeptidyl peptidase-4 inhibitors (DPP-4) and GLP-1 receptor agonists also have intrinsic anti-inflammatory properties, however, beyond their anti-diabetic effects, the contribution of inflammation reduction to diabetes and cardiovascular improvements remains unknown.151–153 Finally, a new class of anti-diabetic drugs, sodium–glucose cotransporter-2 inhibitors (SGLT2 inhibitors) acts by increasing renal excretion of glucose. Preliminary data in humans demonstrate a possible improvement on the circulating biomarkers of inflammation by SGLT2-inhibitors; however, more studies are needed.152

Anti-Inflammatory Drugs in Type 2 Diabetes

Multiple medical approaches that directly target inflammatory pathways have been studied in the past few years supporting the concept of anti-inflammatory treatment for cardiometabolic diseases, such as diabetes and atherosclerotic CVD.154–156 For a long time, salicylates, especially aspirin, have been used to treat thrombosis in primary and secondary CVD prevention, as well as to treat rheumatoid diseases.157,158 They were the first class of drugs reported to lower glucose in diabetes more than a century ago, however, several studies with salicylate products have demonstrated an improved metabolic profile in patients with obesity and diabetes, suggesting a potential efficacy for diabetes prevention and control.159–166

Methotrexate is a disease-modifying drug broadly used to treat rheumatic diseases among other conditions, while its efficacy on glycaemic control was demonstrated in a small cohort study.167 The preliminary data drove the design and conduction of a large clinical trial with methotrexate among patients with previous MI and either T2D or metabolic syndrome, however, methotrexate had neutral findings on IL-1b, IL-6 and CRP levels, while more data are anticipated for the effects on T2D.168

Representative Clinical Trials Of Anti-Inflammatory

Open in new tab
Open ppt

Biological Agents as Anti-Inflammatory Therapy in Type 2 Diabetes

Targeting cytokine production and secretion to prevent further activation of inflammation have been proposed with the intention of stopping the initiation and progression of T2D. TNF-alpha antagonists have been used to treat inflammatory conditions and have been associated with improved glycaemic control and decreased incident of diabetes, while more studies on patients with unfavourable cardiometabolic profile did not demonstrate adequate results, with the exception of a randomised 6-month trial.169–180

The mechanism of action of IL-1beta is consistent with the pathogenesis and progression of T2D is. Improved beta cell secretory function and glycaemia, as well as reduced inflammatory biomarkers in people with diabetes and pre-diabetes have been demonstrated by IL-1beta antagonists, such as anakinra and gevokizumab.112,120,181–6 Studies on CVD and atherosclerosis prevention with IL-1beta antagonists have also been conducted. One study showed that canakinumab reduced the inflammatory proteins CRP, IL-6, and fibrinogen in persons with T2D and high cardiovascular risk with no effect on HbA1C, glucose, and insulin at 4 months, while the large randomised trial with canakinumab – Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) – over a median period of 3.7 years did not reduce the incidence of diabetes in patients with prior MI and high-sensitivity CRP (hsCRP) ≥2 mg/l (Table 2).187,188

Future Perspectives for the Treatment of Diabetes

Novel approaches on T2D to evaluate anti-inflammatory diets and modulate an individual’s microbiome are under study. Clinical trials investigating the effects of vitamin D supplementation on serum levels of inflammatory markers have provided inconsistent results, with no evidence of effects in most trials, or effects on selected markers in others. There are also studies investigating whether antagonists of leukotriene production enzymes – 5-lipoxygenase (5-LO), 5-LO-activating protein and LTA4 hydrolase – or receptor binding BLT1 have cardiometabolic outcome benefits, however these results have not yet been reported. The potential for targeting cholinergic pathways, immune modulation or other mediators of inflammation such as JNK and toll-like receptors (TLRs) are also being researched.

Conclusion

The increasing prevalence of diabetes makes it imperative that research should focus on its prevention as well as its treatment. An improved understanding of the mechanisms linking inflammation to diabetes and related complications has stimulated interest in targeting inflammatory pathways as part of the strategy to prevent or control diabetes and its complications.

T1D is considered to be more of an immunological response rather than a metabolic disorder and the preliminary results of trials using anti-inflammatory and immunomodulatory medication are promising. These treatments in combination with possible use of stem cells to regenerate pancreatic beta cells could potentially be the key to permanent treatment of T1D. Therefore, after a holistic review of the possible mechanisms that lead to T1D and T2D and the numerous already described inflammation pathways that are involved, it becomes more and more clear that future research should focus on simultaneous suppression of various inflammatory response pathways rather than focusing on one pathway at a time.

References
  1. Inzucchi SE. Diagnosis of diabetes. N Engl J Med 2013;368:193.
    Crossref | PubMed
  2. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-23.
    Crossref | PubMed
  3. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.
    Crossref | PubMed
  4. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29–36.
    Crossref | PubMed
  5. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013;34:2444–52.
    Crossref | PubMed
  6. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311–21.
    Crossref | PubMed
  7. WHO. Global report on diabetes. Geneva: WHO, 2016.
  8. Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus. Handb Clin Neurol 2014;126:211–22.
    Crossref | PubMed
  9. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes – 2018. Diabetes Care 2018;41(Suppl 1):S13–27.
    Crossref | PubMed
  10. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14.
    Crossref | PubMed
  11. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129–40.
    Crossref | PubMed
  12. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793–801.
    Crossref | PubMed
  13. Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1901;1:760–2.
    Crossref | PubMed
  14. Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. Br Med J 1957;2:1071–4.
    Crossref | PubMed
  15. Shulman GI. Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology (Bethesda) 2004;19:183–90.
    Crossref | PubMed
  16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87–91.
    Crossref | PubMed
  17. Ogston D, McAndrew GM. Fibrinolysis in obesity. Lancet 1964;2:1205–7.
    Crossref | PubMed
  18. Fearnley GR, Vincent CT, Chakrabarti R. Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet 1959;2:1067.
    Crossref | PubMed
  19. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132–40.
    Crossref | PubMed
  20. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9.
    Crossref | PubMed
  21. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799–805.
    Crossref | PubMed
  22. Marques-Vidal P, Schmid R, Bochud M, et al. Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study. PLoS One 2012;7:e51768.
    Crossref | PubMed
  23. Kengne AP, Batty GD, Hamer M, et al. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care 2012;35:396–403.
    Crossref | PubMed
  24. Goldfine AB, Fonseca V, Shoelson SE. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem 2011;57:162–7.
    Crossref | PubMed
  25. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69–82.
    Crossref
  26. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes develop?: the notion of homicide or beta-cell suicide revisited. Diabetes 2011;60:1370–9.
    Crossref | PubMed
  27. Willcox A, Richardson SJ, Bone AJ, et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009;155:173–81.
    Crossref | PubMed
  28. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279–83.
    Crossref | PubMed
  29. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221–9.
    Crossref | PubMed
  30. Hyttinen V, Kaprio J, Kinnunen L, et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 2003;52:1052–5.
    Crossref | PubMed
  31. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447–85.
    Crossref | PubMed
  32. El-Sheikh A, Suarez-Pinzon WL, Power RF, Rabinovitch A. Both CD4+ and CD8+ T cells are required for IFN-gamma gene expression in pancreatic islets and autoimmune diabetes development in biobreeding rats. J Autoimmun 1999;12:109–19.
    Crossref | PubMed
  33. Miller BJ, Appel MC, O’Neil JJ, Wicker LS. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988;140:52–8.
    PubMed
  34. Phillips JM, Parish NM, Raine T, et al. Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations. Rev Diabet Stud 2009;6:97–103.
    Crossref | PubMed
  35. Richardson SJ, Morgan NG, Foulis AK. Pancreatic pathology in type 1 diabetes mellitus. Endocr Pathol 2014;25:80–92.
    Crossref | PubMed
  36. Healey D, Ozegbe P, Arden S, et al. In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J Clin Invest 1995;95:2979–85.
    Crossref | PubMed
  37. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268:1185–8.
    Crossref | PubMed
  38. Arif S, Leete P, Nguyen V, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014;63:3835–45.
    Crossref | PubMed
  39. Hutchings P, Rosen H, O’Reilly L, et al. Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature 1999;348:639–42.
    Crossref | PubMed
  40. Rodriguez-Calvo T, Ekwall O, Amirian N, et al. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes 2014;63:3880–90.
    Crossref | PubMed
  41. Valle A, Giamporcaro GM, Scavini M, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013;62:2072–7.
    Crossref | PubMed
  42. Dotta F, Censini S, van Halteren AG, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 2007;104:5115–20.
    Crossref | PubMed
  43. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010;10:501–13.
    Crossref | PubMed
  44. Feuerer M, Shen Y, Littman DR, et al. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009;31:654–64.
    Crossref | PubMed
  45. Thomas HE, Darwiche R, Corbett JA, Kay TW. Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 2002;51:311–6.
    Crossref | PubMed
  46. Arif S, Moore F, Marks K, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011;60:2112–9.
    Crossref | PubMed
  47. Moore F, Colli ML, Cnop M, et al. PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis. Diabetes 2009;58:1283–91.
    Crossref | PubMed
  48. Pirot P, Eizirik DL, Cardozo AK. Interferon-gamma potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms. Diabetologia 2006;49:1229–36.
    Crossref | PubMed
  49. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143–52.
    Crossref | PubMed
  50. Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 2014;37:453–9.
    Crossref | PubMed
  51. Roep BO, Solvason N, Gottlieb PA, et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med 2013;5:191ra82.
    Crossref | PubMed
  52. Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 2013;149:268–78.
    Crossref | PubMed
  53. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244–9.
    Crossref | PubMed
  54. Gottlieb PA, Alkanani AK, Michels AW, et al. alpha1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1beta responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab 2014;99:E1418–26.
    Crossref | PubMed
  55. Badenhoop K, Kahles H, Penna-Martinez M. Vitamin D, immune tolerance, and prevention of type 1 diabetes. Curr Diab Rep 2012;12:635–42.
    Crossref | PubMed
  56. Ataie-Jafari A, Loke SC, Rahmat AB, et al. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin Nutr 2013;32:911–7.
    Crossref | PubMed
  57. Gabbay MA, Sato MN, Finazzo C, et al. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual beta-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 2012;166:601–7.
    Crossref | PubMed
  58. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381:1905–15.
    Crossref | PubMed
  59. Saad MF, Knowler WC, Pettitt DJ, et al. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989;1:1356–9.
    Crossref | PubMed
  60. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925–9.
    Crossref | PubMed
  61. Jallut D, Golay A, Munger R, et al. Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism 1990;39:1068–75.
    Crossref | PubMed
  62. Tabák AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373:2215–21.
    Crossref | PubMed
  63. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663–72.
    Crossref | PubMed
  64. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787–835, ix.
    Crossref | PubMed
  65. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014;59:713–23.
    Crossref | PubMed
  66. DeFronzo RA, E. Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38:387–95.
    Crossref
  67. Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? BMC Med 2014;12:123.
    Crossref | PubMed
  68. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008;51:1781–9.
    Crossref | PubMed
  69. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–34.
    Crossref | PubMed
  70. Thorand B, Löwel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93–9.
    Crossref | PubMed
  71. Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res 2017;113:1074–86.
    Crossref | PubMed
  72. Hirosumi J, Tuncman G, Chang Let al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333–6.
    Crossref | PubMed
  73. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860–7.
    Crossref | PubMed
  74. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219–46.
    Crossref | PubMed
  75. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011;121:2111–7.
    Crossref | PubMed
  76. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175–84.
    Crossref | PubMed
  77. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15:914–20.
    Crossref | PubMed
  78. Takaoka M, Nagata D, Kihara S, et al. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009;105:906–11.
    Crossref | PubMed
  79. Sacks H, Symonds ME. Anatomical locations of human brown adipose tissue: functional relevance and implications in obesity and type 2 diabetes. Diabetes 2013;62:1783–90.
    Crossref | PubMed
  80. Sidossis L, Kajimura S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Invest 2015;125:478–86.
    Crossref | PubMed
  81. Lee P, Greenfield JR, Ho KK, Fulham MJ. A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2010;299:E601–6.
    Crossref | PubMed
  82. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169–80.
    Crossref | PubMed
  83. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494–505.
    Crossref | PubMed
  84. Antonopoulos AS, Margaritis M, Coutinho P, et al. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 2015;64:2207–19.
    Crossref | PubMed
  85. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009;10:269–79.
    Crossref | PubMed
  86. Nikolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun 2011;12:239–50.
    Crossref | PubMed
  87. Sandoval D. Bariatric surgeries: beyond restriction and malabsorption. Int J Obes (Lond) 2011;35(Suppl 3):S45–9.
    Crossref | PubMed
  88. Papamargaritis, D, Panteliou E, Miras AD, le Roux CW. Mechanisms of weight loss, diabetes control and changes in food choices after gastrointestinal surgery. Curr Atheroscler Rep 2012;14:616–23.
    Crossref | PubMed
  89. Miras AD, le Roux CW. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes (Lond) 2014;38:325–33.
    Crossref | PubMed
  90. Hartstra AV, Bouter KE, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 2015;38:159–65.
    Crossref | PubMed
  91. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027–31.
    Crossref | PubMed
  92. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913–6.e7.
    Crossref | PubMed
  93. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012;336:1262–7.
    Crossref | PubMed
  94. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012;336:1268–73.
    Crossref | PubMed
  95. Burcelin R, Garidou L, Pomie C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin Immunol 2012;24:67–74.
    Crossref | PubMed
  96. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012;3:279–88.
    Crossref | PubMed
  97. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–72.
    Crossref | PubMed
  98. Hersoug LG, Møller S, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev 2016;17:297–312.
    Crossref | PubMed
  99. Remely M, Aumueller E, Merold C, et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene 2014;537:85–92.
    Crossref | PubMed
  100. Alvarez-Curto E, Milligan G. Metabolism meets immunity: The role of free fatty acid receptors in the immune system. Biochem Pharmacol 2016;114:3–13.
    Crossref | PubMed
  101. Scheithauer TP, Dallinga-Thie GM, de Vos WM, et al. Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Mol Metab 2016;5:759–70.
    Crossref | PubMed
  102. Nastasi C, Candela M, Bonefeld CM, et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep 2015;5:16148.
    Crossref | PubMed
  103. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013;504:451–5.
    Crossref | PubMed
  104. Inatomi O, Andoh A, Kitamura K, et al. Butyrate blocks interferon-gamma-inducible protein-10 release in human intestinal subepithelial myofibroblasts. J Gastroenterol 2005;40:483–9.
    Crossref | PubMed
  105. Brooks-Worrell B, Palmer J. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012;167:40–6.
    Crossref | PubMed
  106. Ahlqvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem 2011;57:241–54.
    Crossref | PubMed
  107. Halban PA, Polonsky KS, Bowden DW, et al. beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014;37:1751–8.
    Crossref | PubMed
  108. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007;56:2356–70.
    Crossref | PubMed
  109. Kamata K, Mizukami H, Inaba W, et al. Islet amyloid with macrophage migration correlates with augmented beta-cell deficits in type 2 diabetic patients. Amyloid 2014;21:191–201.
    Crossref | PubMed
  110. Eguchi K, Manabe I, Oishi-Tanaka Y, et al. Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab 2012;15:518–33.
    Crossref | PubMed
  111. Jourdan T, Godlewski G, Cinar R, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 2013;19:1132–40.
    Crossref | PubMed
  112. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012;35:1654–62.
    Crossref | PubMed
  113. Sauter NS, Schulthess FT, Galasso R, et al. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008;149:2208–18.
    Crossref | PubMed
  114. Butcher MJ, Hallinger D, Garcia E, et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. Diabetologia 2014;57:491–501.
    Crossref | PubMed
  115. Brooks-Worrell BM, Boyko EJ, Palmer J. Impact of islet autoimmunity on the progressive beta-cell functional decline in type 2 diabetes. Diabetes Care 2014;37:3286–93.
    Crossref | PubMed
  116. Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1beta production and beta-cell dysfunction. Diabetes 2014;63:1698–711.
    Crossref | PubMed
  117. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999;48:738–44.
    Crossref | PubMed
  118. Maedler K, Oberholzer J, Bucher P, et al. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003;52:726–33.
    Crossref | PubMed
  119. Böni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009;150:5218–29.
    Crossref | PubMed
  120. Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008;93:4065–74.
    Crossref | PubMed
  121. Arafat HA, Katakam AK, Chipitsyna G, et al. Osteopontin protects the islets and beta-cells from interleukin-1 beta-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology 2007;148:575–84.
    Crossref | PubMed
  122. Yang J, Chi Y, Burkhardt BR, et al. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. Nutr Rev 2010;68:270–9.
    Crossref | PubMed
  123. Dedon PC, Tannenbaum SR. Reactive nitrogen species in the chemical biology of inflammation. Arch Biochem Biophys 2004;423:12–22.
    Crossref | PubMed
  124. Akash MS, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 2012;101:1647–58.
    Crossref | PubMed
  125. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008;14:222–31.
    Crossref | PubMed
  126. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007;36:91–6.
    Crossref | PubMed
  127. Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 2002;51:3176–88.
    Crossref | PubMed
  128. Sell HC, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012;8:709–16.
    Crossref | PubMed
  129. Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013;19:358–63.
    Crossref | PubMed
  130. Cai D. Neuroinflammation in overnutrition-induced diseases. Vitam Horm 2013;91:195–218.
    Crossref | PubMed
  131. Varma V, Yao-Borengasser A, Rasouli N, et al. Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab 2009;296:E1300–10.
    Crossref | PubMed
  132. Kampoli AM, Tousoulis D, Briasoulis A, et al. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011;17:4147–58.
    Crossref | PubMed
  133. Papaoikonomou S, Tousoulis D, Tentolouris N, et al. The role of C-reactive protein genetic variability in the onset of carotid artery disease and renal function impairment in patients with diabetes mellitus type 2. Int J Cardiol 2013;168:4331–2.
    Crossref | PubMed
  134. Chow LS, Odegaard AO, Bosch TA, et al. Twenty year fitness trends in young adults and incidence of prediabetes and diabetes: the CARDIA study. Diabetologia 2016;59:1659–65.
    Crossref | PubMed
  135. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014;2:474–80.
    Crossref | PubMed
  136. Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res 2012;61:789–807.
    Crossref | PubMed
  137. Derosa G, Maffioli P, Sahebkar A. Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;81:819–34.
    Crossref | PubMed
  138. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014;37:912–21.
    Crossref | PubMed
  139. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–207.
    Crossref | PubMed
  140. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924–9.
    Crossref | PubMed
  141. Tousoulis D, Koniari K, Antoniades C, et al. Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. Int J Cardiol 2011;149:46–9.
    Crossref | PubMed
  142. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257–65.
    PubMed
  143. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759–63.
    Crossref | PubMed
  144. Pradhan AD, Everett BM, Cook NR, et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009;302:1186–94.
    Crossref | PubMed
  145. Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004;89:3943–8.
    Crossref | PubMed
  146. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004;89:5043–7.
    Crossref | PubMed
  147. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006;47:1183–8.
    Crossref | PubMed
  148. Kim J, Kwak HJ, Cha JY, et al. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J Biol Chem 2014;289:23246–55.
    Crossref | PubMed
  149. Kim SA, Choi HC. Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun 2012;425:866–72.
    Crossref | PubMed
  150. Vasamsetti SB, Karnewar S, Kanugula AK, et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 2015;64:2028–41.
    Crossref | PubMed
  151. Kim, SC, Wu S, Fang X, et al. Postconditioning with a CpG containing oligodeoxynucleotide ameliorates myocardial infarction in a murine closed-chest model. Life Sci 2014;119:1–8.
    Crossref | PubMed
  152. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–705.
    Crossref | PubMed
  153. Katsi VK, Michalakeas CA, Grassos CE, et al. Canagliflozin: a new hope in the antidiabetic armamentarium. Recent Pat Cardiovasc Drug Discov 2013;8:216–20.
    Crossref | PubMed
  154. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014;13:465–76.
    Crossref | PubMed
  155. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013;339:172–7.
    Crossref | PubMed
  156. Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010;140:935–50.
    Crossref | PubMed
  157. Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:804–13.
    Crossref | PubMed
  158. Frantz B, O’Neill EA. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995;270:2017–9.
    Crossref | PubMed
  159. Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008;1:36–43.
    Crossref | PubMed
  160. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289–94.
    Crossref | PubMed
  161. Faghihimani E, Aminorroaya A, Rezvanian H, et al. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract 2012;18:826-33.
    Crossref | PubMed
  162. Faghihimani E, Aminorroaya A, Rezvanian H, et al. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2013;50:537–43.
    Crossref | PubMed
  163. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013;56:714–23.
    Crossref | PubMed
  164. Goldfine AB, Fonseca V, Jablonski KA, et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2013;159:1–12.
    Crossref | PubMed
  165. Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010;152:346–57.
    Crossref | PubMed
  166. Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother 2010;44:1207–21.
    Crossref | PubMed
  167. de Rotte MC, de Jong PH, den Boer E, et al. Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis. Arthritis Rheumatol 2014;66:2026–36.
    Crossref | PubMed
  168. Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752–62.
    Crossref | PubMed
  169. Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004;34:641–2.
    Crossref | PubMed
  170. Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765–6.
    Crossref | PubMed
  171. Yazdani-Biuki B, Mueller T, Brezinschek HP, et al. Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care 2006;29:1712–3.
    Crossref | PubMed
  172. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83–6.
    PubMed
  173. Huvers FC, Popa C, Netea MG, et al. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007;66:558–9.
    Crossref | PubMed
  174. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007;20:731–6.
    Crossref | PubMed
  175. Timper K, Hruz P, Beglinger C, Donath MY. Infliximab in the treatment of Crohn disease and type 1 diabetes. Diabetes Care 2013;36:e90–1.
    Crossref | PubMed
  176. Ofei F, Hurel S, Newkirk J et al. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881–5.
    Crossref | PubMed
  177. Paquot N, Castillo MJ, Lefèbvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 200;85:1316–9." target="_blank">Crossref | PubMed
  178. Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517–25.
    Crossref | PubMed
  179. Bernstein LE, Berry J, Kim S, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006;166:902–8.
    Crossref | PubMed
  180. Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011;96:E146–50.
    Crossref | PubMed
  181. Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663–8.
    Crossref | PubMed
  182. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517–26.
    Crossref | PubMed
  183. van Asseldonk EJ, Stienstra R, Koenen TB, et al. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011;96:2119–26.
    Crossref | PubMed
  184. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab 2013;39:524–31.
    Crossref | PubMed
  185. Rissanen A, Howard CP, Botha J, et al. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012;14:1088–96.
    Crossref | PubMed
  186. Sloan-Lancaster J, Abu-Raddad E, Polzer Jet al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 2013;36:2239–46.
    Crossref | PubMed
  187. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126:2739–48.
    Crossref | PubMed
  188. Everett BM, Donath MY, Pradhan AD, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol 2018;71:2392–401.
    Crossref | PubMed
  189. Alhadj Ali M, Liu YF, Arif S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med 2017;9:eaaf7779.
    Crossref | PubMed
  190. Pitocco D, Crinò A, Di Stasio E, et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMDIAB XI). Diabet Med 2006;23:920–3.
    Crossref | PubMed
  191. Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Pediatr Diabetes 2011;12:656–67.
    Crossref | PubMed
  192. Cabrera SM, Wang X, Chen YG, et al. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. Eur J Immunol 2016;46:1030–46.
    Crossref | PubMed
  193. van Asseldonk EJ, van Poppel PC, Ballak DB, et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol 2015;160:155–62.
    Crossref | PubMed
  194. van Poppel PC, van Asseldonk EJ, Holst JJ, et al. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab 2014;16:1269–73.
    Crossref | PubMed
  195. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009;52:385–93.
    Crossref | PubMed
  196. Ramos-Zavala MG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, González-López R, Santiago-Hernández NJ. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care 2011;34:1591–4.
    Crossref | PubMed